Target Audience

Activity description

Learning objectives

Faculty and disclosure statement

Accreditation

This activity will be of relevance to hematologists, oncologists, critical care specialists and infectious disease specialists. In addition, this program will provide useful information and guidance to all medical professionals who should be aware of the latest developments in fungal infections.

Welcome to this exciting CME-accredited activity "Advancing the Art of Antifungal Therapy: New therapeutic options and treatment strategies".

There has recently been an increase in both the choice of treatment options and available clinical information for the treatment of systemic fungal infections. This wide range of information can prove to be overwhelming for the physician who must select the best treatment strategy for their patients. This webcast will review available clinical data in support of various treatment options and approaches in order to provide clear guidance to physicians.

On completion of this activity, the participant should be able to:

• Review the epidemiology of fungal infections in immunosuppressed patients
• Compare the different treatment approaches to fungal infections
• Discuss the clinical indications for each treatment approach
• Analyze the latest clinical data on therapeutic options
• Evaluate the optimal treatment strategy for their individual patients.

Thomas F. Patterson, MD, FACP
Professor of Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, TX

CME Consultants, Inc. holds the standard that its continuing medical education activities be free of commercial bias.

Now, in accordance with the disclosure policy of CME Consultants, Inc., as well as standards set forth by the ACCME, the ANCC and the ACPE, faculty have been asked to disclose any relationship they have to companies producing pharmaceuticals, medical equipment, prostheses, etc. that might be germane to the content of their lectures and any relationship they have with the commercial supporter(s) of the activity. Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide registrants with information that might be of potential importance to their evaluation of a given talk. The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA approved uses of pharmaceuticals, medical equipment, prostheses, etc. will be included in their presentation.

Faculty have reported receiving something of value* from a company whose product may be germane to the content of their presentations.

Name	Relationship	Company
Thomas F. Patterson	Consultant	BMS, Fujisawa, Merck, Microbia, Pfizer, Schering-Plough, Uriach Versicor
	Grant support	Fujisawa, Merck, Pfizer, Schering-Plough
	Speaker bureau	Merck, Pfizer

* "Something of value" refers to an equity position, vested interest, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for education services elsewhere, or to any other relationship to a company that provides suffi cient reason for disclosure, in keeping with the spirit of the stated policy.